` SLRX (Salarius Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

SLRX
vs
S&P 500

Over the past 12 months, SLRX has underperformed S&P 500, delivering a return of -97% compared to the S&P 500's +14% growth.

Stocks Performance
SLRX vs S&P 500

Loading
SLRX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
SLRX vs S&P 500

Performance Gap Between SLRX and GSPC
HIDDEN
Show

Performance By Year
SLRX vs S&P 500

Loading
SLRX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Salarius Pharmaceuticals Inc vs Peers

S&P 500
SLRX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Salarius Pharmaceuticals Inc
Glance View

Market Cap
4m USD
Industry
Biotechnology

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The company is headquartered in Houston, Texas and currently employs 16 full-time employees. The company went IPO on 2015-01-29. In addition, the Company is also developing treatments for cancers caused by dysregulated gene expression. The firm is developing two classes of drugs that address gene dysregulation: epigenetic drugs and targeted protein degraders. The Company’s technologies have the potential to work in both liquid and solid tumors. The Company’s pipeline consists of two compounds: seclidemstat (SP-2577), which is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (LSD1); SP-2577 uses a reversible mechanism to inhibit LSD1’s enzymatic and scaffolding properties and thereby treat and prevent cancer progression, and SP-3164, which is a cereblon binding molecular glue and has a development path in hematological cancer and potential in solid tumors.

SLRX Intrinsic Value
Not Available
Back to Top